Prevalence, relative thrombosis risk, and average blood counts stratified by JAK2V617F VAFs from the Danish Suburban Population Study.³⁷  Mean blood counts of 19 313 patients with JAK2V617F⁻ (nonmutated), 508 patients with JAK2V617F⁺ (<1% VAF) non-MPN, 105 patients with JAK2V617F⁺ (≥1% VAF) non-MPN, and 16 patients with MPN (14 of whom were JAK2V617F⁺ with VAF 0.3% to 96%) (upper panel). The numbers in each group (left vertical axis) and the corresponding odds ratios for venous thromboembolism (VTE) and ischemic cerebrovascular disease (ICVD) compared with the nonmutated group (right vertical axis) (lower panels). Hg, hemoglobin. *Significantly different compared with nonmutated; ^#significantly different compared with JAK2V617F⁺ <1% VAF.